Cargando…

Prevalence and Clinical Significance of Occult Hepatitis B Infection in The Gambia, West Africa( )

BACKGROUND: Prevalence and clinical outcomes of occult hepatitis B infection (OBI) have been poorly studied in Africa. METHODS: Using the PROLIFICA cohort, we compared the prevalence of OBI between hepatitis B surface antigen (HBsAg)-negative healthy adults screened from the general population (cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndow, Gibril, Cessay, Amie, Cohen, Damien, Shimakawa, Yusuke, Gore, Mindy L, Tamba, Saydiba, Ghosh, Sumantra, Sanneh, Bakary, Baldeh, Ignatius, Njie, Ramou, D’Alessandro, Umberto, Mendy, Maimuna, Thursz, Mark, Chemin, Isabelle, Lemoine, Maud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470103/
https://www.ncbi.nlm.nih.gov/pubmed/34160616
http://dx.doi.org/10.1093/infdis/jiab327
Descripción
Sumario:BACKGROUND: Prevalence and clinical outcomes of occult hepatitis B infection (OBI) have been poorly studied in Africa. METHODS: Using the PROLIFICA cohort, we compared the prevalence of OBI between hepatitis B surface antigen (HBsAg)-negative healthy adults screened from the general population (controls) and HBsAg-negative patients with advanced liver disease (cases), and estimated the population attributable fraction for the effect of OBI on advanced liver disease. RESULTS: OBI prevalence was significantly higher among cases (15/82, 18.3%) than controls (31/330, 9.4%, P = .03). After adjusting for age, sex, and anti-hepatitis C virus (HCV) serology, OBI was significantly associated with advanced liver disease (odds ratio, 2.8; 95% confidence interval [CI], 1.3–6.0; P = .006). In HBsAg-negative people, the proportions of advanced liver disease cases attributable to OBI and HCV were estimated at 12.9% (95% CI, 7.5%–18.1%) and 16.9% (95% CI, 15.2%–18.6%), respectively. CONCLUSIONS: OBI is endemic and an independent risk factor for advanced liver disease in The Gambia, West Africa. This implies that HBsAg-negative people with liver disease should be systematically screened for OBI. Moreover, the impact of infant hepatitis B immunization to prevent end-stage liver disease might be higher than previous estimates based solely on HBsAg positivity.